Mercurio, Jean-Pierre Di
https://orcid.org/0009-0005-9067-4934
Mayo Clinic
Hôpital Arnaud de Villeneuve
Citations 1
A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC.
Camidge, D. Ross , Demedts, Ingel , Grosch, Heidrun, Mercurio, Jean-Pierre Di , Molina, Julian R. , Bepler, Gerold , Lewanski, C., Wijayawardana, Sameera R. , Wang, Xuejing Aimee , Morán, Teresa , Mileham, Kathryn Finch , Juan, Óscar , Goldman, Jonathan W. , Park, Keunchil , Wallin, Johan Erik , Wacheck, Volker , Smit, Egbert F
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 9070-9070
